We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Mature blood cells arise from hematopoietic stem cells (HSCs) capable of generating every hematopoietic cell type; including the various lymphoid and myeloid lineages. To maintain the steady state levels of hematopoietic cells in the circulation, each HSC has the capacity to generate large numbers of mature cells daily via various multi- and oligopotent lineage-committed progenitors (Kondo et al., 2003; Orkin, 2000). Finely tuned self-renewal and differentiation programs, controlled by essential transcriptional regulatory networks (Miranda-Saavedra & Gottgens, 2008), determine the HSC and progenitor pool sizes in adults. These regulatory networks include both positive and negative transcriptional regulators that control lineage specific gene expression and ensure normal hematopoietic cell differentiation. Deregulation of these transcriptional networks caused by aberrant upstream signalling, point mutations as well as chromosomal translocations of key transcriptional regulators particularly within the HSC compartment (Bonnet & Dick, 1997) can lead to various blood related disorders including anemia and hematological malignancies or leukemia.

The origins of HSCs during the development of a mammalian embryo are only beginning to be understood. Tracing of the true stem cells via marker analysis is difficult and the ‘gold standard’ for identifying these cells is based on their ability to reconstitute lethally irradiated hosts over a long term. Various transplantation studies in the mouse (Dzierzak & Medvinsky, 2008) have revealed that HSCs arise in a complex developmental process during which multipotent progenitors sequentially migrate to several anatomical sites (Dzierzak & Speck, 2008; Orkin & Zon, 2008), including the yolk sac, the aorta-gonadomesonephros (AGM) region, placenta, fetal liver and finally the bone marrow in the adult (Palis et al., 2001). Lately, it is thought that the first definitive adult-type of HSCs are generated in the AGM region at embryonic day (E) 10.5 in the mouse (de Bruijn et al., 2002). It was demonstrated through fate mapping that the first HSCs arise as part of the hematopoietic progenitor clusters that emerge from the hemogenic endothelium and subendothelial layers at the ventral part of the dorsal aorta and in the vitelline artery (Rybtsov et al., 2011; Yokomizo et al., 2011). These small cell clusters of hematopoietic progenitors are closely associated with the endothelium and originate from vascular remodelling and extravascular budding (Boisset et al., 2010; Robin et al., 2011; Zovein et al., 2010). This involves changes in endothelial cell shape and loss of cellular adhesion that have
been likened to the changes in cell adhesion that epithelial cells undergo during epithelial to mesenchymal transition (EMT). EMT encompasses a series of events in which well-polarized epithelial cells round up in shape, lose their cell contacts and acquire the motile, migratory properties of mesenchymal cells (Greenburg & Hay, 1982). EMT is essential for many developmental processes including mesoderm formation during gastrulation and neural crest delamination and migration (Kalluri & Weinberg, 2009; Thiery et al., 2009). Similar EMT-like changes in cellular morphology can be observed during tumor progression and allow tumor cells to acquire the capacity to invade into the surrounding tissue and ultimately metastasize to a distant site (Bex et al., 2007). Subsequent tissue colonization occurs via a reverse transitional mechanism, called mesenchymal to epithelial transition (MET) (Kalluri, 2009). Significant cross talk and interactions between members of the Snai family and Zeb family of transcription factors have been documented to be involved in the regulation of these EMT/MET processes (Thiery & Sleeman, 2006). More recently, it has been suggested that the expression of the EMT regulators are also involved in the formation/acquisition of (cancer) stem cell properties (Gupta et al., 2009). In addition to their roles in epithelial/mesenchymal biology there is accumulating evidence that these EMT inducers may be involved in several aspects of hematopoietic differentiation and hematological malignancies that is the main focus of this chapter and are reviewed below.

2. EMT regulators of the Snai family

Members of Snai family encode for transcription factors with a common structural organization consisting of a highly conserved C-terminal region with four to six C₂H₂ zinc-fingers (Knight & Shimeld, 2001) and a more divergent N-terminal region (Fig. 1). This zinc-finger domain serves as a sequence-specific DNA binding domain that recognizes consensus E2-box type elements C/A(CAGGTG) (Batlle et al., 2000; Cano et al., 2000; Mauhin et al., 1993). All vertebrate Snai family members share as well an evolutionary conserved 7-9 AA N-terminus, the SNAG (Snail/Gfi) domain (Grimes et al., 1996). This domain was originally identified as a repressor domain in the zinc-finger protein Gfi1 that acts as a molecular hook to recruit co-regulators and/or demethylases and is essential for their Snai transcriptional repressive function (Lin et al., 2010).

Snail (also known as Snai1, Sna, Snah, Slugh2, Snai1.) represents the founding member of the superfamily (Manzanares et al., 2001; Nieto, 2002) and was first described in Drosophila melanogaster (Grau et al., 1984). In mammals, besides Snail two other Snail family members were identified Slug (aka Snai2, Slugh1, Slugh, Snai2) and Smuc (aka Snai3, Zfp293, Znf293). Snail and Slug are the best characterized and have been implicated in the formation of the mesoderm (Boulay et al., 1987; Sefton et al., 1998) and neural crest cell migration (del Barrio & Nieto, 2002; LaBonne & Bronner-Fraser, 2000) as well as with the loss of epithelial features associated with the acquisition of a fibroblast-like motile and invasive phenotype of tumor cells. Induced expression of Snail or Slug in various epithelial cancer cell lines either by FGF, Wnt, Notch or TGFβ administration (De Craene et al., 2005) or directly via ectopic expression of the repressors is sufficient to adopt a more mesenchymal morphology (Cano et al., 2000). This phenotypic switch is characterized by the downregulation of a number of epithelial marker genes (E-cadherin, desmoplakin, Muc-1, cytokeratin-18) (Batlle et al., 2000; Cano et al., 2000) and the induction of various mesenchymal marker genes (vimentin, fibronectin) (Cano et al., 2000), which can vary dependent on the cellular context. Several
lines of evidence indicated that Snail family members not only regulate cellular adhesion and motility or invasion but as well can bind and regulate genes that participate in other processes (Wu Y. & Zhou, 2010) like proliferation (CyclinD1) (Liu J. et al. 2010), cell survival/apoptosis (BID, caspase-6) (Kajita et al., 2004), inflammation (Lyons et al., 2008; Yang & Wolf, 2009) and angiogenesis (Gill et al. 2011).

![Diagram of conserved functional domains of the three members of the Snail family of transcription factors](image.png)

Besides this, Snai gain-of-function is correlated with the acquisition of (cancer) stem cell properties (Gupta et al., 2009). Studies of various neoplastic tissues have demonstrated the existence of cancer stem cells (CSC) or tumor-initiating-cells with self-renewal capacity that exhibit an ability to induce new tumors when transplanted into nude and/or syngeneic mouse strains (Schatton et al., 2009). The existence of CSCs was initially discovered in leukemia samples (Bonnet & Dick, 1997), but subsequently they have been identified in various solid tumor types as well (Al-Hajj et al., 2003; Ricci-Vitiani et al., 2007; Singh et al., 2004). The origin of these stem cells is until now unclear but compelling results from Mani and colleagues (Mani et al., 2008) now link EMT processes with the formation of CSCs. Ectopic expression of Snail in an immortalized human mammary epithelial cell line resulted in the acquisition of mesenchymal traits, expression of stem cell markers and enhanced capacity to form mammospheres, a property previously and exclusively associated with mammary epithelial stem cells. For now it is unclear whether this is restricted to cancer stem cells of an epithelial origin or can be generalized to all (cancer) stem cells. Somewhat contradictory to this, is the recent findings that suppression of EMT inducers and the expression of E-cadherin is one of the first essential steps during the reprogramming of fibroblasts for the generating induced pluripotent stem cells (Li et al., 2010; Redmer et al., 2011; Wang et al., 2010). This may reflect the fact that stemness properties and totipotency are not equivalent and may be controlled by divergent molecular mechanisms.
Recently, the *in vivo* functions of Snail and Slug could be further analyzed by the generation of novel gain/loss-of-function mouse models. Here we shall focus more on the hematopoietic phenotypes observed in these mouse models.

### 2.1 Slug is an important downstream mediator of SCF/cKit signaling and plays pivotal roles in stress-induced hematopoietic stem/progenitor cell survival and self-renewal

The first evidence of an important role for Slug in hematopoiesis and leukemia came from study by Inukai et al. (1999) in which Slug was identified as a downstream target of the E2A-HLF oncogene in leukemic B-cells. The E2A-HLF fusion gene transforms human pro-B lymphocytes by interfering with the apoptotic signaling pathway at an early step. Moreover, Slug expression in IL3-dependent Baf-3 cells prolonged the survival of these cells significantly after deprivation of the cytokine. These initial data suggested a pivotal role for Slug in the cell survival pathway of lymphocyte progenitor cells and possibly as well in other hematopoietic progenitors, based on its expression profile. Endogenous Slug is normally expressed in both long- and short-term repopulating HSCs and in committed progenitors of the myeloid lineage but not in differentiated myeloid cells or pro-B or pro-T cells. Its role in other lineages was further investigated *in vivo* by the generation of Slug deficient mice. Mice lacking Slug survive and are fertile, but display postnatal growth retardation phenotypes (Inoue et al., 2002). Upon loss of Slug, normal circulating blood cell counts were observed but the number of hematopoietic colony-forming progenitors in the bone marrow and spleen were significantly (2-4-fold) increased. This suggested that in the absence of Slug, hematopoietic progenitor pools must expand to maintain normal levels of differentiated blood cells in the circulation. In addition, Slug deficient mice are more radiosensitive; these mice not only died earlier upon γ-irradiation, but as well showed accentuated decreases in peripheral blood cell counts and marked increases in apoptotic (TUNEL+) bone marrow progenitors cells compared to their control littermates. These data implicated an important role for Slug in protecting hematopoietic progenitor cells from apoptosis after DNA damage (Inoue et al., 2002). By crossing the Slug knockout mice with various other mouse models it was demonstrated that Slug directly represses the proapoptotic factor Puma and in this way is able to antagonize the p53-mediated upregulation of Puma in γ-irradiated myeloid progenitor cells, allowing them to survive (Wu W.S. et al., 2005). All together these data suggest that Slug governs a pivotal checkpoint that controls cell survival/apoptosis decisions upon exposure to genotoxic stress.

The role of Slug in the regulation of the bone marrow stem cell compartment was further investigated under both normal steady-state and stress conditions via competitive repopulating assays and serial bone marrow transplants (Sun et al., 2010). Under normal conditions, Slug deficiency seems to have no effect on proliferation or differentiation of HSC or progenitors. However, if transplanted, Slug null HSCs demonstrated increased repopulating potential that was not a result of altered differentiation nor homing ability, suggesting Slug deficiency alters HSC self-renewal. Indeed this was confirmed under the stress conditions of serial bone marrow transplantation. Consistently, 5-FU treatment of Slug knockout mice showed an expansion of the Lin-Sca1+ cell population, not by changing their cell survival capacity but by increasing their proliferation rates (Sun et al., 2010).

More detailed analysis of Slug deficient mice revealed macrocytic anemia as well as pigmentation deficiency and gonadal defects (Perez-Losada et al., 2002). These phenotypes
are very similar to the defects reported in the white-spotting (W) and Steel (Sl) mutant mice with mutations in the c-Kit receptor (Chabot et al., 1988; Geissler et al., 1988) and its Stem Cell Factor (SCF) ligand (Copeland et al., 1990; Huang et al., 1990; Zsebo et al., 1990). The SCF/c-Kit signaling pathway has pleiotrophic functions in hematopoiesis and beyond. The primary function of SCF/c-Kit in early hematopoiesis seems to induce the growth of quiescent progenitor/stem cells through synergistic interactions with other early-acting cytokines (Migliaccio et al., 1991; Williams N. et al., 1992). Ample evidence indicates that in the absence of other cytokines, SCF selectively promotes viability rather than proliferation of primitive murine progenitor cells (Fleming et al., 1993) and confirms previous findings of Slug playing a role in both cell cycle/proliferation and cell survival/apoptosis. Next to its role in hematopoiesis, SCF/c-Kit signaling has been implicated in the development/migration of melanocytes (Nishikawa et al., 1991). In human piebaldism patients, c-Kit signaling has been demonstrated to be involved in congenital depigmented patches and poliosis, (Giebel & Spritz, 1991). Interestingly in some piebaldism patients, also heterozygous SLUG deletions could be detected, providing further genetic evidence that Slug may play crucial roles in the SCF/c-Kit signaling pathway (Sanchez-Martin et al., 2003). The importance of Slug as a putative downstream mediator of c-Kit signaling was further tested by means of a complementation study in which transduction with TAT-Slug protein was sufficient to rescue the radio-sensitivity of c-Kit deficient mice. Taken together these data clearly demonstrate that Slug is an important mediator downstream of c-Kit receptor activation (Perez-Losada et al., 2003).

The observed macrocytic anemia observed in the Slug mutant mice resemble in some ways human congenital anemias such as Diamond-Blackfan anemia (Perez-Losada et al., 2002), however more research is necessary to explore the involvement of Slug in this disease.

2.2 Snail and Smuc in normal hematopoiesis

Mice deficient for Snail are embryonic lethal at E7.5-8.5 due to defects in mesoderm formation (Carver et al., 2001) as well as vascular defects (Lomeli et al., 2009). Consequently, due to the early embryonic lethality, the effects of Snail loss on hematopoiesis could not be further investigated in these mice. Although some evidence exists that Snail is expressed in the hematopoietic system, more detailed research is necessary and final proof of its potential role in hematopoiesis will come from breeding the conditional floxed Snail mice (Murray S.A. et al., 2006) to mice with hematopoietic-specific transgenic Cre lines.

Based upon the fact that in vitro Snail binds similar E-box binding domains and in general shows more drastic phenotypes both in vitro as in vivo compared to Slug, Snail may also play crucial roles in hematopoiesis. Interestingly, Snail and Slug in most cases can complement each other and differences in phenotypes can be explained by differences in expression patterns as exemplified by the aggravated phenotypes of the Snail/Slug double knockouts (Murray S.A. et al., 2007). In addition, loss of one Snai family member often induces or increases the expression of the other(s). In this way hematopoietic-specific double knockouts may reveal even more functions for Snail and Slug in normal hematopoiesis.

More recently a third family member of the Snail family was identified in vertebrates, Smuc. Until now, little is known about its functions but it is abundantly expressed in thymocytes (Zhuge et al., 2005), specifically in the early CD4-CD8- double negative (DN) and
CD4+CD8+ double positive (DP) stages of thymocyte maturation and then solely expressed in the CD8+ T lymphocyte lineage both in the thymus and peripheral immune system. In macrophages, Smuc is able to interact with PU.1, a master regulator of myeloid differentiation, and binds the negative regulatory element within the Pactolus promoter. These data suggest that Smuc is modulating the PU.1 transcriptional activity and lack of Smuc leads to aberrant PU.1 transactivation (Hale et al., 2006).

2.3 Overexpression of Snail or Slug induces leukemia

Based on the prominent roles of Snail and Slug in stress-induced hematopoiesis, and their roles in the progression of solid tumours, as well as acquisition of cancer stem cell characteristics, it is therefore surprising that only a limited number of studies have addressed the roles of Snai family members in hematopoietic malignancies.

Nevertheless, strong evidence that Snail and Slug are involved in leukemia formation and/or progression comes from the gain-of-function mouse models that were previously developed. CombiTA-Snail mice, carrying a hypermorphic tetracycline-repressible Snail transgene, showed increased Snail expression up to 20% above normal levels (Perez-Mancera et al., 2005b). These mice survive and are fertile and although no morphological alterations were observed, their thymus were smaller and showed reduced differentiation towards CD4+CD8+ DP thymocytes. From 5-7 months onwards, CombiTA-Snail mice started to develop various types of epithelial and non-epithelial cancers especially lymphomas and acute leukemias (> 75% in two separate transgenic lines). Suppression of the Snail transgene expression by tetracycline administration did not ameliorate the malignant phenotype, suggesting that the effect of Snail overexpression is irreversible. As well, CombiTA-Snail transgene expression resulted in increased in vivo radioprotection, suggesting similar roles for Snail in hematopoietic cell survival upon genotoxic stress as was previously shown for Slug.

Similar experiments were performed for in vivo overexpression of Slug. In a similar setup as described above for Snail, CombiTA-Slug mice were generated. To prove transgene functionality, these mice were crossed with Slug deficient mice, which rescued the null phenotype. Again these mice were born without overt morphological abnormalities (Perez-Mancera et al., 2006). Only after 6-8 months 20% of the transgenic mice died as a consequence of congestive heart failure. The surviving mice started to develop various tumors from 9 months of age with highest incidence of (90%) acute leukemias (Perez-Mancera et al., 2005a). Similar as to the CombiTA-Snail mice this malignant phenotype was irreversible after tetracycline administration. As well, c-Kit signaling has been implicated both in solid tumors as well as leukemias, e.g. constitutive activating mutations of the receptor have been described in AML (Jung et al., 2011) Furthermore, the BCR–ABL oncogene did not induce leukaemia in Slug-deficient mice, implicating Slug in BCR–ABL leukemogenesis in vivo (Perez-Mancera et al., 2005a). As well, in an independent study it was shown that the increased Slug expression upon Bcr-Abl mutations is involved in the prolonged survival of chronic myeloid leukemia cells (Mancini et al., 2010).

From the Slug knockout mice it appears that it is governing a pivotal role in cell survival upon DNA damage by repressing the pro-apoptotic factor Puma. These results may be highly relevant for cancer therapy. Analyzing or controlling Slug levels before or during...
treatment may be useful as a prognostic marker for sensitivity to genotoxic agents and can be helpful for limiting therapeutic doses or increasing the efficiency of radiation or chemotherapy.

3. EMT regulators of the Zeb family

The Zinc finger E-Box binding (ZEB) family of DNA-binding transcriptional regulators consists of two structurally related proteins (Fortini et al., 1991) (Fig. 2): Zeb1 (also known as δEF-1, TCF8, BZP, ZEB, AREB6, NIL-2-A, Zfhx1a and Zfhx1b) and Zeb2 (also known as Sip1, KIAA0569 and Zfhx1b). Both genes have a very similar genomic structures (Fortini et al., 1991; Vandewalle et al., 2009) and encode for large multi-domain proteins that possess N-terminal and C-terminal zinc finger DNA binding domains along with more centrally located homeo (HD), Smad protein binding (SBD) and CtBP interaction (CID) domains; and in the case of Zeb2, an N-terminal NuRD interaction domain (Verstappen et al., 2008).

Fig. 2. Schematic diagram of conserved functional domains of the two members of the Zeb family of transcription factors. Both possess 2 zinc-finger domains, a homeodomain (HD), Smad (SBD) and CtBP (CID) binding domain (Figure based on Vandewalle et al., 2009).

Especially within the Zn-finger domains there exists a high degree of sequence similarity/identity between the two Zeb proteins, suggesting they bind similar target sequences (Verschueren et al., 1999). Each Zn-finger cluster independently can bind a 5'-CACCT(G)-3' sequence located in the target promoter region (Remacle et al., 1999). The domains outside the Zn-finger clusters seem less conserved and may be essential for the recruitment of various co-repressors, like CtBP (Grooteclaes & Frisch, 2000; Postigo & Dean, 1999b; van Grunsven et al., 2007) or co-activators like p300 or P/CAF (van Grunsven et al., 2006). Still a lot of controversy exists over whether Zeb proteins can only act as transcriptional repressors or as well as activators. The molecular mechanism underlying the choice between repression or activation are currently unknown and may include cell-type specific differences and/or posttranslational modifications (Costantino et al., 2002). Similarly, the roles of Zeb proteins in TGFβ/BMP signaling are not well understood; both Zeb2 have been shown to be able to bind receptor activated R-Smads (Postigo, 2003; Verschueren et al., 1999). Postigo et al. (Postigo, 2003) postulated Zeb proteins as putative important downstream mediators of this signaling pathway however with opposing effects. While Zeb1 would synergize with Smad proteins to activate transcription of TGFβ
responsive reporter constructs, the structurally very similar Zeb2 would inhibit transcriptional activation downstream of TGFβ (Postigo, 2003). These antagonistic effects were hypothesized to result from differential recruitment of co-activators and co-repressors to the Smads by Zeb1 or Zeb2 respectively (Postigo et al., 2003).

The Zeb family of zinc finger/homeodomain proteins genes was first identified in Drosophila melanogaster (Fortini et al., 1991) and shown to be essential for myogenesis (Postigo et al., 1999) and the organization of the central nervous system (Clark & Chiu, 2003). As well in vertebrates a vast number of muscle master regulatory genes have been shown to be repressed directly by Zeb1/2 (α7 integrin, δ crystalin enhancer, Mef2c) (Postigo & Dean, 1997, 1999a) as well as genes essential for cartilage and bone formation (Col2α1) (Murray D. et al., 2000). The first functional studies in Xenopus proved Zeb1 to be essential for the expression of XBra (Xenopus Brachyury) (Papin et al., 2002), a member of T-box family of transcription factor essential for mesoderm formation and notochord differentiation and previously been implicated in EMT processes. Subsequently various in vitro studies using multiple epithelial cancer cell lines, it was demonstrated that both Zeb1/2 are able to bind and downregulate E-cadherin (Comijn et al., 2001; Eger et al., 2005) and other epithelial-specific marker genes via binding bipartite E-boxes in their promoter regions. Exogeneous Zeb1/2 overexpression results in EMT-like phenotypes similarly as described above for the Snai family members of EMT inducers (Comijn et al., 2001; Vandewalle et al., 2005). Increased in vivo Zeb1/2 expression has been correlated in various tumor types with increased invasion, metastasis, dedifferentiation, cancer stem cell characteristics, recurrence and bad prognosis (Spaderna et al., 2006; Spoelstra et al., 2006; Wellner et al., 2009; Yoshihara et al., 2009).

Besides their roles in suppression of epithelial marker genes more and more studies revealed their participation in other cellular processes like cell division (Mejlvang et al., 2007), apoptosis and senescence (Liu Y. et al., 2008; Ozturk et al., 2006; Sayan et al., 2009) and inflammation (Chua et al., 2007).

From expression analysis it was clear that both Zeb proteins are also expressed in the hematopoietic system. Actually, Zeb1 has been demonstrated to be more expressed during T-lymphocyte development, while Zeb2 expression has been seen more in splenic B cells (Postigo & Dean, 2000). Using various novel mouse models recent data clearly indicated that this family of EMT inducers also plays pivotal roles in various steps of hematopoietic differentiation and progression of hematopoietic malignancies, which are discussed in detail below.

3.1 Role of Zeb2 in hematopoietic stem/progenitor differentiation and mobilization

Moderate to high Zeb2 expression is reported in all hematopoietic cells with highest levels in stem (HSC) and progenitor (HPC) populations (Goossens et al., 2011) and lowest expression in mature T cells (Postigo & Dean, 2000). Through the use of a conditional Zeb2 knockout mouse (Higashi et al., 2002) model we could show that it is not essential for the initial formation of HSCs in the embryo but it is crucial for HSC differentiation and mobilization/homing (Goossens et al., 2011). Hematopoietic-specific Zeb2 loss-of-function resulted in embryonic lethality resulting from bleedings occurring in the developing brain. The observed phenotype is very reminiscent of the phenotypes associated with ubiquitous loss of the hematopoietic transcriptional regulators AML/Runx1 (Okuda et al., 1996). Runx1 knockout embryos are deficient in AGM HSCs and lack intra-arterial hematopoietic clusters,
suggesting that Zeb2 deletion may also affect hematopoietic cluster formation. However, no changes in the number of hematopoietic progenitor clusters was detected for the Zeb2 null AGM regions (Goossens et al., 2011) indicating that the formed stem cells are not functional at later stages of development. Zeb2 seems to be more involved in stem/progenitor differentiation properties as isolated progenitors from various developing hematopoietic organs were unable to differentiate in vitro. As well, significant decreases in fully differentiated hematopoietic cells were observed. Next to this differentiation block, an increased adhesion/clustering of hematopoietic cells in the fetal liver and less mobile progenitors in the peripheral blood were observed. It was hypothesized that the increased levels of Cxcr4 within the Zeb2 null progenitors lead to their retention in the fetal liver that resulted in less progenitors in the embryonic circulation. This decreased mobilization of hematopoietic progenitors likely contributed to the decreased levels of angiogenic factors (like Ang1) within the circulation, thereby resulting in less maturation and pericyte recruitment towards the newly formed vessels in the developing brain. Most probably this defect contributed to the observed cephalic bleeding phenotype. From this initial data it has become clear that Zeb2 is not only a crucial transcriptional regulator of hematopoietic differentiation but as well plays pivotal roles in the mobilization and homing of HSCs within the embryo (Goossens et al., 2011). More experiments need to be performed to analyze whether this also holds true in adult hematopoiesis.

3.2 Role of Zeb1 in T cell development

Neonatal Zeb1 total knockout mice die shortly after birth. Drastic skeletal abnormalities (Takagi et al., 1998) and serious thymic atrophy were observed. Through the use of a second Zeb1 loss-of-function mouse model, expressing a C-terminal zinc finger truncation allowed survival to adulthood, it was feasible to further investigate the in vivo role of Zeb1 in adult hematopoiesis (Higashi et al., 1997). In these ΔC-fin mice no skeletal phenotypes were observed. On the other hand T lymphocyte differentiation was drastically impaired. This observation points towards the hypothesis that different domains of Zeb1 are responsible for alternative/synergistic functions, which as well was hypothesized previously by Postigo and colleagues via their in vitro approaches described above (Postigo & Dean, 1999a). More detailed FACS analysis of Zeb1 ΔC-fin mutant thymocytes revealed a block at a very early stage in the cKit+ CD4− CD8− DN population, before rearrangements of the T cell receptor (TCR) locus (Higashi et al., 1997). Only a very small proportion of the intrathymic T cell precursors (<1% compared of the normal T cell development) was able to differentiate further and expressed differentiated T cell markers. These differentiated cells were skewed mainly towards CD4+CD8− SP cells, indicated that also at later stages of T cell development Zeb1 expression may play essential roles. More recently it was shown that Zeb1 binds the 5’ E-boxes in the proximal enhancer of the CD4 promoter and competes with the transcriptional activators E12 and HEB for DNA binding. Therefore it was concluded that overexpression of Zeb1 in T cells converts the CD4 proximal enhancer into a silencer element leading to a reduction of CD4 expression. This data shows that the CD4 gene is a direct target of the transcriptional repressor Zeb1 and can explain the increased proportion of CD4+CD8−SP mature T cells in Zeb1 mutant mice (Brabletz et al., 1999).

Another known downstream target of Zeb1 during myogenesis is α4-integrin. Also in hematopoietic differentiation of various lineages α4-integrin is known to play crucial roles
through its interaction with fibronectin and V-CAM in the stromal matrix and stromal cells of the bone marrow and fetal liver. α4-integrin is highly expressed in stem and progenitor cells and upon further differentiation its expression is restricted to lymphocytes and myeloid subpopulations. Zeb1 binds and directly represses α4-integrin expression (Postigo & Dean, 1999a). Previously it was shown that α4 integrin expression depends on C-Myb and Ets family of transcription factors. Based on in vitro α4-integrin promoter analysis, Postigo (Postigo & Dean, 1997) concluded that Zeb1 blocks activity of c-Myb and Ets individually but together these synergize to overcome Zeb1 repression. Next to CD4 and α4 integrin, Zeb1 has been suggested to repress a number of other genes implicated in proper T cell differentiation like Gata3 (Gregoire & Romeo, 1999), immunoglobulin heavy chain enhancer (Genetta et al., 1994) and interleukin-2 (Williams T.M. et al., 1991; Yasui et al., 1998).

Within B-lymphocytes a functional cooperation between FoxO transcription factors and Zeb1 has been revealed. Zeb1 binds and activates two promoters of known FoxO target genes cyclin G2 and retinoblastoma-like 2. Both have been implicated in cell cycle arrest and Foxo-dependent quiescence in fibroblasts (Chen et al., 2006). However a role of Zeb1 in B-cell development has not been reported.

### 3.3 Role of Zeb1/2 in T and B cell acute lymphoblastic leukemia

Using the same ΔC-fin Zeb1 mutant mice described above it was demonstrated that expression of the truncated Zeb1 protein resulted in the development of spontaneous CD4+ T-cell lymphomas with a median onset at 30 weeks of age. This is consistent with the fact that ZEB1 expression is frequently lost in human adult T-cell leukemia/lymphoma (T-ALL) patients (Hidaka et al., 2008; Vermeer et al., 2008). In T-ALL cell lines it was demonstrated that the tumour cell’s resistance to TGF-β mediated growth suppression is via up-regulation of the inhibitory Smad7 (Nakahata et al., 2010). Here the role of Zeb proteins in the regulation of Smad7 remains needs to be better understood. Similarly the actual role of the other above described Zeb1 targets remains to be determined in T cell lymphomas.

The role of Zeb1 in B-Cell leukemia has not been reported. However, in terms of hematological malignancy, some independent genome-wide retroviral insertional mutagenesis screens have identified Zeb2 and not Zeb1 as a possible gene involved in mouse B-cell lymphoma progression (Lund et al., 2002; Mikkers et al., 2002; Shin et al., 2004). From these initial studies it was not clear if Zeb2 expression is lost due to retroviral integration and translocation events or enhanced during the transformation process. More recently in CALM-AF10 transgenic mice, enhanced Zeb2 expression was found to correlate with increased leukemia progression (Caudell et al., 2010). Additionally, knockdown of Zeb2 in a B-ALL cell line resulted in decreased proliferation rates. However in vivo Zeb2 overexpression studies are missing to be conclusive concerning the role of Zeb2 in leukemogenesis. Nevertheless, ZEB2 genomic locus rearrangements are commonly associated with aggressive B cell lymphomas in humans as well (Matteucci et al., 2008).

### 4. Conclusions

From the above literature survey it is clear that EMT inducers of the Snai and Zeb families play crucial and yet specific roles during various stages of hematopoiesis and leukemic transformation. These specific roles are in some way surprising given that they all bind
similar E box-containing DNA sequences and a significant overlap in target genes has been reported. This can in some ways be explained by differences in their expression patterns and/or the recruitment of other cell-specific co-repressors and/or activators.

As well, the above reviewed data clearly indicate crucial roles for the EMT inducers of the Zeb and Snai family in different aspects of hematopoiesis: differentiation, proliferation, apoptosis/survival, mobilization, stemness, as well as quiescence. All of this suggests that these two family of proteins might be excellent targets for developing novel and improved cancer therapies not only as was suggested before for solid tumours but as well for blood-borne cancers and other haematological defects associated with improper lineage differentiation.

5. Acknowledgment

This work was partially supported by the European Hematology Association (EHA Young Investigator Fellowship 2009/26 to SG). SG is a postdoctoral fellow of the Basic Science Research Foundation-Flanders (FWO).

6. References


www.intechopen.com


progression in cells undergoing an epithelial mesenchymal transition. *Molecular biology of the cell*, Vol.18, No.11, pp. 4615-4624


www.intechopen.com
The Role of EMT Modulators in Hematopoiesis and Leukemic Transformation


transcription factors: Deltaef1 family members bind with two hands to two target sites. *The EMBO journal*, Vol.18, No.18, pp. 5073-5084


Hematology encompasses the physiology and pathology of blood and of the blood-forming organs. In common with other areas of medicine, the pace of change in hematology has been breathtaking over recent years. There are now many treatment options available to the modern hematologist and, happily, a greatly improved outlook for the vast majority of patients with blood disorders and malignancies. Improvements in the clinic reflect, and in many respects are driven by, advances in our scientific understanding of hematological processes under both normal and disease conditions. Hematology - Science and Practice consists of a selection of essays which aim to inform both specialist and non-specialist readers about some of the latest advances in hematology, in both laboratory and clinic.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.